Compositions and methods for treating autoimmune disease

Details Compositions and methods for treating autoimmune disease Compositions and methods for treating autoimmune disease

1998-01-21

2000-08-08

Yu, Mickey

Surgery

Miscellaneous

Methods

435 6, A61B 1900

Patent

active

06098631&

ABSTRACT:
Methods and compositions are described for treating and diagnosing autoimmune diseases, and in particular for treating and detecting rheumatoid arthritis. Treatment is described with a new class of anti-RA drug, namely compounds that inhibit proliferation and induce apoptosis.

REFERENCES:
patent: 5137919 (1992-08-01), Igarashi et al.
patent: 5151360 (1992-09-01), Handa et al.
patent: 5248828 (1993-09-01), Saito et al.
patent: 5260288 (1993-11-01), Igarashi et al.
patent: 5331014 (1994-07-01), Kimura et al.
patent: 5391800 (1995-02-01), Igarashi et al.
patent: 5466716 (1995-11-01), Igarashi et al.
patent: 5583160 (1996-12-01), Igarashi et al.
patent: 5627171 (1997-05-01), Park et al.
patent: 5677189 (1997-10-01), Igarashi et al.
patent: 5712262 (1998-01-01), Spiegel
patent: 5871930 (1999-02-01), Bandman et al.
R. Million et al., "Long-Term Study of Management of Rheumatoid Arthritis," Lancet 1:812-816 (1984).
J. A Engelbrecht et al., "Methotrexate Pneumonitis After Low-Dose Therapy for Rheumatoid Arthritis," Arthritis and Rheumatism 26(10):1275-1278 (1983).
G. W. Cannon et al., "Acute Lung Disease Associated With Low-Dose Pulse Methotrexate Therapy In Patients With Rheumatoid Arthritis," Arthritis and Rheumatism 26(10):1269-1274 (1983).
Simon and Mills, "Nonsteroidal Antiinflammatory Drugs," N. Eng. J. Med. 302(21):1179-1243 (1980).
W. Katz et al., "Proteinuria in Gold-Treated Rheumatoid Arthritis," Ann. Int. Med. 101:176-179 (1984).
W. F. Kean et al., "The Toxicity Pattern Of D-Penicillamine Therapy," Arthritis and Rheumatism 23(2):158-164 (1980).
S. Nagata, "Fas and Fas Ligand: A Death Factor and Its Receptor," Advances in Immunology 57:129-144 (1994).
R. N. Kolesnick et al., "The Sphingomyelin Signal Transduction Pathway Mediates Apoptosis For Tumor Necrosis Factor, Fas, and Ionizing Radiation," Biochem. Cell Biol. 72:471-474 (1994).
M. Verheij et al., "Requirement for ceramide-initiated SAPK/JNK signaling in stress-induced apoptosis," Nature 380:75-79 (1996).
C. J. van Koppen et al, "Activation of a High Affinity G.sub.i Protein-coupled Plasma Membrane Receptor by Sphingosine-1-phosphate," J. Biol. Chem. 217(4):2082-2087 (1996).
O. Cuvillier et al., "Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate," Nature 381:800-803 (1996).
A. Abbas, "Die and Let Live: Eliminating Dangerous Lymphocytes," Cell 84:655-657 (1996).
C. Jacob et al., "Heterogeneous effects of IFN-.gamma. in adjuvant arthritis," J. Immunol 142(5):1500-1505 (1989).
K. Goodemote et al., "Involvement of a Pertussis Toxin-sensitive G Protein in the Mitogenic Signaling Pathways of Sphingosine 1-Phosphate," J. Biol. Chem. 270:10272-10277 (1995).
G. H. Fisher et al., "Dominant Interfering Fas Gene Mutations Impair Apoptosis in a Human Autoimmune Lymphoproliferative Syndrome," Cell 81:935-946 (1995).
F. Rieux-Laucat et al., "Mutations in Fas Associated with Human Lymphoproliferative Syndrome and Autoimmunity," Science 268:1347-1349 (1995).
M. Adachi et al., "Aberrant Transcription Caused by the Insertion of an Early Transposable Element in an Intron of the Fas Antigen Gene of Ipr Mice," Proc. Natl. Acad. Sci. (USA) 90:1756-1760 (1993).
B. S. Andrews et al., "Spontaneous Murine Lupus-Like Syndromes: Clinical and Immunopathological Manifestations in Several Strains," J. Exp. Med. 148:1198-1215 (1978).
H. Takayama et al., "Cytotoxic T Lymphocytes: The Newly Identified Fas (CD95)-Medicated Killing Mechanism and a Novel Aspect of Their Biological Functions," Adv. Immunol. 60:289-321 (1995).
D. W. Nicholson et al., "Identification and Inhibition of the ICE/CED-3 Protease Necessary for Mammalian Apoptosis," Nature 376:37-43 (1995).
M. Tewari et al., "Yama/CPP32.beta., a Mamalian Homolog of CED-3, Is a CrmA-Inhibitable Protease That Cleaves the Death Substrate Poly (ADP-Ribose) Polymerase," Cell 81:801-869 (1995).
A. M. Chinnaiyan et al., "FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis," Cell 81:505-512 (1995).
S. M. Krane and R.T. Salzman, "Management of Rheumatoid Arthritis and Osteoarthritis; Therapeutic Challenges, Problems and Possibilities," Am J. Med. :75(4B):1-91(1983).
D. E. Furst, "Are There Differences Among Nonsteroidal Antiinflammatory Drugs; Comparing Acetylated Salicylates, Nonacetylated Salicylates, and Nonacetylated Nonsteroidal Antiinflammatory Drugs," Arth. & Rheum. 37(1):1-9 (1994).
B. O. Barger et al., "DR Antigens and Gold Toxicity In White Rheumatoid Arthritis Patients," Arth. & Rheum. 27(6):601-605 (Jun. 1984).
H. B. Stein et al., "Adverse Effects of D-Penicillamine in Rheumatoid Arthritis," Ann. Int. Med. 92:24-29 (1980).
C. J. Marshall, "Hot Lips and Phosphorylation of Protein Kinases," Nature 367:686 (1994).
G. L'Allemain, "Deciphering the Map Kinase Pathway," Progress in Growth Factor Research 5:291-334 (1994).
S. A. Susin et al., "The Central Executioner of Apoptosis: Multiple Connections Between Protease Activation and Mitochondria in Fas/APO/CD95-and Ceramide-Induced Apoptosis," J. Exp. Med.186(1):25-37 (1997).

Affiliated with

Also associated with

Rating

Compositions and methods for treating autoimmune disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for treating autoimmune disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating autoimmune disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1140542